Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2074761. doi: 10.1080/21645515.2022.2074761. Epub 2022 Jun 13.
Getting vaccinated against SARS-CoV-2 lowers the risk of severe infections. In Hong Kong, two vaccine types are offered: CoronaVac by Sinovac Biotech (Sinovac), and Comirnaty by BioNTech-Fosun Pharma (BioNTech). However, a low vaccine uptake rate is observed. This study primarily aimed to determine the population of medical students who underwent COVID-19 vaccination, and to identify factors associated with their decision on timing and vaccine type. Current medical students from The University of Hong Kong (HKU) were invited to participate in this cross-sectional survey study from 16 September to 31 December 2021. The main outcome measures were the vaccine uptake rate, primary reasons for vaccine-seeking behavior, vaccine hesitancy and vaccine preference, as well as information sources. All questions were of a multiple-choice format, with a free response option for questions pertaining to reason exploration. Overall, 214 medical students participated in the study, with all questionnaires analyzed. Amongst the 98.1% that completed 2 doses, 93.4% selected BioNTech and 6.6% selected Sinovac. Significant associations were observed between year groups and vaccine timing (p = 0.00989). The primary reason to seek vaccination was immunity against COVID-19 (53.5%), while the fear of potential side effects (61.6%) accounted for vaccine hesitancy. The BioNTech vaccine was favored for its higher efficacy against COVID-19 (87.4%). Information sources were mainly from HKU professors (64.6%) and social media (59.9%). The study found a high vaccine uptake rate amongst medical students, contrary to the situation observed in the Hong Kong general population at the time of the study.
接种 SARS-CoV-2 疫苗可降低重症感染的风险。在香港,提供了两种疫苗类型:科兴生物(Sinovac)的克尔来福(CoronaVac)和复星医药/辉瑞(BioNTech)的复必泰(Comirnaty)。然而,疫苗接种率较低。本研究主要旨在确定接受过 COVID-19 疫苗接种的医学生人群,并确定与他们对疫苗接种时间和疫苗类型的决定相关的因素。本研究于 2021 年 9 月 16 日至 12 月 31 日期间邀请香港大学(HKU)的现任医学生参加这项横断面调查研究。主要观察指标为疫苗接种率、寻求疫苗接种的主要原因、疫苗犹豫和疫苗偏好以及信息来源。所有问题均采用多项选择格式,对于与原因探索相关的问题提供了自由回答选项。共有 214 名医学生参与了该研究,所有问卷均进行了分析。在完成两剂疫苗接种的 98.1%学生中,93.4%选择了辉瑞(BioNTech),6.6%选择了科兴生物(Sinovac)。各年级组与疫苗接种时间之间存在显著相关性(p=0.00989)。寻求接种疫苗的主要原因是对 COVID-19 的免疫力(53.5%),而对潜在副作用的恐惧(61.6%)导致了疫苗犹豫。辉瑞(BioNTech)疫苗因其对 COVID-19 的更高疗效而受到青睐(87.4%)。信息来源主要来自 HKU 教授(64.6%)和社交媒体(59.9%)。研究发现医学生的疫苗接种率较高,与研究时香港一般人群的情况相反。